StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) income statement

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54+0.01 (+0.18%)

Close on Nov 19, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics Inc income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
68.8%
Operating margin
-12.2%
Net margin
-14.0%
Return on equity, FY2025
-68.5%

Financial strength

Current ratio
2.21
Debt to equity
0.40
Debt to assets
18.9%
Cash to current liabilities
88.1%

Valuation

P/E ratio
–
Price to sales
0.66
Price to book
1.74
Dividend yield
–

See a number that looks wrong?